Stockreport

Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs [Yahoo! Finance]

Carisma Therapeutics, Inc.  (CARM) 
PDF Adds proprietary CAR sequence IP to Liberate's selective in vivo delivery platform, strengthening the foundation of its emerging CAR-M therapeutic class CAMBRIDGE, Ma [Read more]